Medtronic Undergoes Leadership Shakeup Amid Sweeping Transformation
Medtronic, the global medical technology company, has announced significant changes to its executive leadership team. In a statement, Rob Hoedt, Executive Vice President and President of Medtronic's global regions, revealed that he will be retiring from his distinguished career on June 28th, opting to start his retirement journey earlier than the company's mandatory retirement age of 65. At 63 years old, ten Hoedt has decided to forgo the remainder of his professional tenure and embark on a new chapter of his retirement life.
Additionally, Karen Parkhill, Executive Vice President and Chief Financial Officer of Medtronic, has announced her plans to depart the company and join the renowned HP Inc. as their new CFO. To ensure the continuity of the company's financial operations, Medtronic has initiated the search for a suitable successor, which may come from within the organization or be an external candidate of exceptional caliber. In the interim, Gary Corona, Senior Vice President of Global Financial Planning and Analysis, will temporarily assume the CFO responsibilities to facilitate a smooth transition.
This year has been a tumultuous one for Medtronic, marked by a series of high-level executive departures. In addition to ten Hoedt and Parkhill's exits, the company has seen the departures of several other senior leaders, including Gio DiNapoli, President of the Gastrointestinal business; Ariel Mactavish, President of the Respiratory Interventions business; Bob White, Executive Vice President and President of the Medical Surgical Portfolio; and Christopher Cleary, Senior Vice President of Corporate Development.
The challenges facing Medtronic this year are part of a comprehensive transformation plan. In February, the company announced the closure of its Respiratory business unit, accompanied by a global workforce reduction, the implementation of an early retirement program, stricter cost control measures, and increased investments in automation, digitalization, and strategic research and development to support the company's future growth. These reform initiatives have been a significant driver behind the recent extensive leadership changes.
Looking for chemical products? Let suppliers reach out to you!
2026-07-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
Recommend Reading
-
West Asia Tensions Squeeze Pharma Raw Materials
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
A Faster Route to Diabetes Drug Chemistry
-
Polyethylene Rises and Then Falls in April; Demand Remains Weak
-
L-Alanine: Amino Acid Profile, Sports Nutrition, and Metabolic Role
-
In the second half of April, the butadiene rubber market in China showed a slight decline
-
Potassium Nitrate Reactions & Uses (KNO3)
-
April Acetic Acid Market Slides Sharply